Preclinical Immunology & Autoimmune Deal Benchmarks

Median Upfront

$61M

Range: $22M - $104M

Total Deal Value

$878M

Range: $395M - $1.4B

Royalty Rate

5.5% - 10.9%

Tiered up to 14.9%

Dev Milestones

$368M

Range: $168M - $566M

Model Your Deal

Market Analysis

Preclinical immunology & autoimmune licensing deals carry a median total deal value of $878M, with upfront payments ranging from $22M to $104M. At this stage, deal structures are heavily milestone-weighted, reflecting the significant clinical risk ahead. The recommended split allocates 7% to upfront and 93% to milestones.

The immunology & autoimmune landscape at the preclinical stage is characterized by high competitive intensity, particularly in inflammatory bowel disease and autoimmune conditions. Development milestones average $368M, regulatory milestones contribute $245M, and commercial milestones reach $204M. CAR-T for autoimmune diseases, TL1A inhibitors, and next-generation targeted therapies are reshaping the licensing landscape.

Royalty rates for preclinical immunology & autoimmune deals range from 5.5% to 10.9% at the base tier, with high-tier escalation to 14.9%. Earlier-stage royalties are at the lower end of industry ranges, reflecting higher clinical risk.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for preclinical immunology & autoimmune deals?

Preclinical immunology & autoimmune deals average $61M in upfront payments, ranging from $22M to $104M. The upfront allocation of 7% of total deal value reflects the clinical stage risk profile.

How are preclinical immunology & autoimmune deal milestones structured?

Milestones account for approximately 93% of total deal value. Development milestones ($368M) represent the largest component, followed by commercial milestones ($204M) and regulatory milestones ($245M).

What royalty rates are typical for preclinical immunology & autoimmune licensing?

Base royalty rates range from 5.5% to 10.9%, with tiered escalation to 9.5%-14.9% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Preclinical Immunology & Autoimmune Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Phase 1 Immunology & Autoimmune Deals

Phase 1/2 Immunology & Autoimmune Deals

Preclinical Oncology Deals

Preclinical Neurology Deals

Ready to Calculate Your Deal Terms?